The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.
Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials
Abstract
Background Diabetes mellitus is a frequent comorbid condition in patients with chronic heart failure (CHF) and confers a worse prognosis. Furthermore, although patients with CHF derive considerable benefit from beta-blockers, these agents are thought by many physicians to be contraindicated in patients with diabetes mellitus. Most published studies on beta-blockers in CHF have been unable to reach definitive conclusions about the mortality benefits of these agents in patients with diabetes mellitus. We therefore performed a meta-analysis of beta-blocker trials that reported mortality outcomes in patients with diabetes mellitus who had CHF to pool all available trial evidence on the benefits (or otherwise) of these agents in this setting.Methods All-cause mortality data on patients with diabetes mellitus were obtained from all completed beta-blocker CHF randomized placebo-controlled trials involving >100 patients exposed to beta-blockers, in which outcomes in patients with diabetes mellitus were described. When events were not directly reported, risk ratios (RRs) were derived from analysis of figures and other manuscript data. Results were pooled with the Mantel-Haenszel method.Results A total of 24.6% of patients were reported to have diabetes mellitus in the 6 studies analyzed (Australia and New Zealand [ANZ]-Carvedilol, Beta-blocker Evaluation of Survival Trial [BEST], Carvedilol US Trials, Cardiac Insufficiency Bisoprolol Study [CIBIS-II], Carvedilol Prospective Randomized Cumulative Survival Trial [COPERNICUS], and Metoprolol Controlled-release Randomized Intervention Trial in Heart Failure [MERIT-HF]). Patients with diabetes mellitus had increased mortality rates overall compared with subjects without diabetes mellitus (RR, 1.25; 95% CI, 1.15-1.36; P <.001). Compared with placebo, beta-blocker therapy for CHF was beneficial in patients with diabetes mellitus (RR, 0.84; 95% CI, 0.73-0.96; P =.011) and in subjects without diabetes mellitus (RR, 0.72; 95% CI, 0.65-0.79; P <.001). The absolute risk reduction in mortality with beta-blocker therapy was greater in patients with heart failure but without diabetes mellitus than in patients with diabetes mellitus (P =.023).Conclusions Patients with diabetes mellitus and CHF appear to derive prognostic benefit from beta-blocker therapy, although the magnitude of that benefit is somewhat less than that observed in subjects without diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a meta-analysis of six trials, beta-blocker therapy reduced all-cause mortality in patients with T2DM (HR 0.84) similarly to those without T2DM (HR 0.72).156”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [156]
Citations
Cites
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
Lechat, P. P., Brunhuber, K., Hofmann, R., Kuhn, P., Nesser, H., Slany, J., Weihs, W., Wiedermann, C. J., Wimmer, H., van Mieghem, W., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,922
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Diabetes and cardiovascular disease
Howard, B. V., & Magee, M. F. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0046-8 · Cited by 1,386
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
Waagstein, F., Hjalmarson, Å. C., Swedberg, K. B., Bristow, M. R., Gilbert, E. M., Camerini, F., Fowler, M. B., Silver, M. A., Johnson, M. R., & Goss, F. (1993) · The Lancet · doi:10.1016/0140-6736(93)92930-r · Cited by 1,223
Research works printed but not linked: 2
- Mohacsi, 2001, Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study, Circulation, 104, II-754
- Chavey, 2001, Guideline for the management of heart failure caused by systolic dysfunction, Am Fam Physician, 64, 1045
Cited by
Sorted by citations
Authors Task Force Members, Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,994
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,644
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,222
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708
Tsutsui, H., Isobe, M., Ito, H., Ito, H., Okumura, K., Ōno, M., Kitakaze, M., Kinugawa, K., Kihara, Y., Goto, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0342 · Cited by 720
Metadata
- Authors
- Haas, S. J., Vos, T., Gilbert, R. E., & Krum, H.
- Affiliations
- The Alfred Hospital (AU)
- The University of Melbourne (AU)
- Corresponding author
- Krum, Henry
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2003-11
- Volume
- 146
- Issue
- 5
- Pages
- 848-853
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W1975966089
- Cited by
- 194
- References
- 41
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 7 · 2020: 18 · 2019: 10 · 2018: 6 · 2017: 9 · 2016: 8 · 2015: 7 · 2014: 12 · 2013: 12 · 2012: 8
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- beta-blockers, chronic heart failure, diabetes mellitus, all-cause mortality, carvedilol, bisoprolol, metoprolol, beta-blocker contraindication, comorbidities
- MeSH terms
- Adrenergic beta-Antagonists, Diabetes Mellitus, Heart Failure, Humans, Comorbidity, Survival Rate, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review